WeVote
Log In

Bill

Bill

SB 1812

Relating to prior authorization for prescription drug benefits related to the treatment of neurodegenerative diseases.

89th Legislature (2025) Introduced by Donna Campbell and 1 co-sponsor

SB 1812 streamlines prior authorization for neurodegenerative disease medications in Texas, potentially accelerating patient access to time-sensitive treatments.

Referred to Health & Human Services
#health--otherdiseases&medicalconditions(i0383) #insurance--health&accident(i0422) #medicine&prescriptiondrugs(s7338)
0
WeVote Research Nonpartisan
Bill Summary · SB 1812

Legislative bill overview

SB 1812 would modify prior authorization requirements for prescription drugs used to treat neurodegenerative diseases in Texas. The bill aims to streamline the approval process for these medications, potentially reducing delays patients face when accessing treatment. Specific provisions have not been detailed in available records, but the measure targets insurance coverage barriers for degenerative neurological conditions.

Why is this important

Neurodegenerative diseases like ALS, Parkinson's, and Alzheimer's often require time-sensitive medication interventions where treatment delays can meaningfully affect patient outcomes. Prior authorization—where insurers must approve medications before coverage—can postpone access by days or weeks. Streamlining this process could improve treatment initiation speed for conditions where disease progression is relentless and irreversible.

Potential points of contention

  • Cost implications: Faster approval pathways may increase utilization of expensive specialty drugs, raising premiums for insurers and employers covering these medications
  • Insurance company flexibility: Stricter prior authorization limits could reduce insurers' ability to manage formularies and negotiate drug pricing
  • Scope definition: The bill's specific inclusion criteria for "neurodegenerative diseases" remain unclear—determining which conditions qualify could create coverage disputes and inconsistencies

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.